Good morning :)
Switch to
Place Order

Glenmark Pharmaceuticals Ltd

GLENMARK
Health CarePharmaceuticals
MidcapWith a market cap of ₹17,675 cr, stock is ranked 227
Moderate RiskStock is 2.00x as volatile as Nifty
626.4023.50 (-3.62%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
MidcapWith a market cap of ₹17,675 cr, stock is ranked 227
Moderate RiskStock is 2.00x as volatile as Nifty

Key Metrics

PE RatioPE Ratio
18.22
PB RatioPB Ratio
2.91
Dividend YieldDiv. Yield
0.40%
Sector PESector PE
40.38
Sector PBSector PB
5.77
Sector Div YldSctr Div Yld
0.61%

Forecast & RatingsDetailed Forecast 

45%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Glenmark Pharmaceuticals Limited is a global pharmaceutical company engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs).

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

See Plans

Financial TrendFinancial statements 

20182019202020219.1710.2410.8311.040.800.920.780.97
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Increased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 1.14%

See detailed holdings

Recent EventsAll events 

Updates 
Announced OnJul 20, 2021

Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Filing and approval of the Red Herring Prospectus ( RHP ) dated July 19, 2021 of our wholly owned subsidiary Glenmark Life Sciences Limited in connection with its proposed initial public offering of equity shares ( Offer or IPO )'. | Download

Glenmark Pharmaceuticals Limited has informed the Exchange regarding 'Filing and approval of the Red Herring Prospectus ( RHP ) dated July 19, 2021 of our wholly owned subsidiary Glenmark Life Sciences Limited in connection with its proposed initial public offering of equity shares ( Offer or IPO )'. | Download

Related Party Transactions 
Announced OnJun 25, 2021

Glenmark Pharmaceuticals Limited has informed the Exchange about related Party Transactions | Download

Glenmark Pharmaceuticals Limited has informed the Exchange about related Party Transactions | Download

Cash Dividend 
Ex. DateSep 17, 2020

Final • Div/Share: ₹ 2.5

See all events